A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

NCT ID: NCT00424931

Last Updated: 2014-05-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2007-12-31

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-17216498 compared to modafinil and placebo in patients with narcolepsy, with and without cataplexy.

Detailed Description

This study with a new, experimental drug is being done to assess safety and tolerability, and to explore effectiveness in the treatment of narcolepsy. Approximately 64 adult patients with narcolepsy with or without cataplexy will be recruited for the study. Patients who meet study criteria will need to stop taking their current narcolepsy and/ or other medication for at least 14 days before checking into the site for 3 nights. They will be randomly assigned to one of 4 treatment arms; each patient has an equal chance of receiving placebo, 10 mg JNJ-17216498, 50 mg JNJ-17216498 or 400 mg modafinil. Placebo has no active drug. Modafinil is a drug currently approved to treat narcolepsy. Patients will take the medication on only one day and will receive study medication in a blinded fashion, i.e. the patient, the doctor and the study sponsor will not know what group the patient is in until all patients complete the study. The investigator and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit and the three nights at the site, there will be a follow-up visit 7-10 days after the day the study drug is taken. After the follow-up visit, patients may resume their previous narcolepsy medications. Medical history, physical examination, vision tests, blood pressure, heart rate, temperature, and ECGs will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. The Maintenance of Wakefulness Test will be done to assess the patient's ability to resist falling asleep while reclining in a dark, quiet room; this will involve completing 7 sessions before dosing and 10 sessions after dosing. Patients will have two polysomnograms, a test of brain, muscle and eye activity during sleep, obtained by recording brain waves and other activities such as muscle and eye movement. Polysomnograms will be obtained overnight, once before and once after dosing. Patients will also complete brief questionnaires about their sleepiness and the status of their narcolepsy throughout the study. Patients will receive capsules containing either 10 mg JNJ-17216498, 50 mg JNJ-17216498, 400 mg modafinil and/or placebo on one day. Seven capsules will be taken orally in the morning and two capsules will be taken orally in the afternoon. Placebo contains no active drug. Modafinil is a drug currently approved to treat narcolepsy.

Conditions

Narcolepsy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

001

JNJ-17216498 10mg one time

Group Type: EXPERIMENTAL

JNJ-17216498

Intervention Type: DRUG

10mg one time

002

JNJ-17216498 50mg one time

Group Type: EXPERIMENTAL

JNJ-17216498

Intervention Type: DRUG

50mg one time

003

Modafinil 200 mg X 2

Group Type: ACTIVE_COMPARATOR

Modafinil

Intervention Type: DRUG

200 mg X 2

Interventions

JNJ-17216498

50mg one time

Intervention Type: DRUG

JNJ-17216498

10mg one time

Intervention Type: DRUG

Modafinil

200 mg X 2

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• diagnosis of narcolepsy within the past 5 years
• good general health
• no history or presence of drug or alcohol abuse

Exclusion Criteria

• current use of prescription or over the counter medications including asprin or herbal supplements with the exception of acetaminophen (Tylenol)
• use of fluoxetine (Prozac) in the past 6 weeks
• use of Xyrem in the past 4 weeks
• use of tobacco products in the past 3 months
• caffeine consumption that is more than 5 cups of tea, or 3 cups of coffee or 8 cans of soda per day

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alza Corporation, DE, USA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alza Corporation Clinical Trial

Role: STUDY_DIRECTOR

ALZA

Locations

Birmingham, Alabama, United States

Phoenix, Arizona, United States

Tucson, Arizona, United States

San Diego, California, United States

Stanford, California, United States

Spring Hill, Florida, United States

St. Petersburg, Florida, United States

Macon, Georgia, United States

Danville, Indiana, United States

Fort Wayne, Indiana, United States

Amherst, New York, United States

Cincinnati, Ohio, United States

Toledo, Ohio, United States

Columbia, South Carolina, United States

Houston, Texas, United States

Spokane, Washington, United States

Countries

United States

Other Identifiers

C-2006-028

Identifier Type: -

Identifier Source: secondary_id

CR013390

Identifier Type: -

Identifier Source: org_study_id